Trials / Completed
CompletedNCT00373516
Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis
A Multi-Center, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Study of the Safety and Efficacy of Two Dosing Regimens of QRX-101 (Becocalcidiol) Ointment in the Treatment of Plaque-Type Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (planned)
- Sponsor
- QuatRx Pharmaceuticals Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of two dosing regimens of QRX-101 ointment (75 mcg/g QD and 75mcg/g BID) in the treatment of plaque-type psoriasis when applied topically twice daily for 8 weeks
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vehicle (Placebo) applied BID | |
| DRUG | QRX-101 75 mcg/g ointment applied QD | |
| DRUG | QRX-101 75 mcg/g ointment applied BID |
Timeline
- Start date
- 2004-09-01
- Completion
- 2005-03-01
- First posted
- 2006-09-08
- Last updated
- 2006-09-08
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00373516. Inclusion in this directory is not an endorsement.